DiaMedic

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for severe neurological and kidney diseases. The company's lead candidate, DM199, is a recombinant form of the human tissue kallikrein-1 (KLK1) protein, which is essential for regulating blood flow, inflammation, and oxidative stress. By restoring KLK1 levels, DiaMedica aims to address the underlying vascular and inflammatory pathologies in conditions such as acute ischemic stroke and chronic kidney disease. The company is currently advancing DM199 through a pivotal Phase 2/3 clinical trial for stroke recovery, targeting significant unmet medical needs in the cardiovascular and renal sectors.